# Caris Life Sciences Inc. (CAI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Industrials / Commercial Services & Supplies. Price $25.07, market value $7.1 billion.

## Valuation
- **P/E (trailing): 2.6×**. Caris Life Sciences Inc. trades at 2.6× trailing earnings. The Industrials median in the September 2026 study was 25.7×. Forward P/E is 66.3×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.95**. A PEG of 0.95 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.2×**. Each dollar of revenue is priced at 7.2×.
- **Price / book: 12.0×**. The shares trade at 12.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 38.3×**. Enterprise value is 38.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.7%** (5-yr avg 1.5%). Free cash flow equals 1.7% of the market value, in line with its five-year average of 1.5%.
- **Earnings yield: 38.2%**. The inverse of the P/E: 38.2% of the price is earned each year.

## Profitability
- **Operating margin: 15.5%**. 15.5% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -8.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -11.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 75.7%**. Return on all capital, debt included, is 75.7%: comfortably above what that capital costs.
- **Return on assets: 9.3%**. Each dollar of assets produces 9.3% of profit.

## Growth
- **Revenue growth (1 yr): 97.0%**. Revenue grew 97.0% over the last year.
- **EPS growth (1 yr): 69.8%**. Earnings per share rose 69.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.66**. Debt is 0.66 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Caris Life Sciences Inc. holds more cash than debt.
- **Altman Z-score: 9.33**. A Z-score of 9.33 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Caris Life Sciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover Caris Life Sciences Inc.; the consensus is buy, with an average price target of $27.00 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -31.0%** (YTD -7.1%, 3-mo 52.0%). The shares are down 31.0% over twelve months including dividends.
- **From 52-week high: -28.8%** (76.7% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.38** (volatility 66%). Beta of 1.38 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CAI · Page: https://foliofundamentals.com/stocks/cai

Not investment advice.